We’re moving! Datasets in the NIAGADS database are being transitioned to the DSS database, click to learn more.

Knight ADRC Collection

The search for novel risk factors and genetic modifiers for Alzheimer disease relies on the access to accurate and deeply phenotyped datasets. The Memory and Aging Project (MAP) at the Knight-ADRC (Washington University in St. Louis) collects cognitive data, CSF and imaging longitudinally.  This clinical information combined with deep molecular phenotyping (i.e. genetic, proteomics, transcriptomics, metabolomics and lipidomics among others) will lead to the identification of novel genetic modifiers, protective variants, molecular biomarkers and the novel targets. Participants were recruited by the Knight-ADRC at Washington University in St. Louis (MO). Knight-ADRC participants have to be at least 65 years old and have no memory problems or mild dementia at the time of enrollment.

The cohort consists of individuals who are non-Hispanic white from North America (95%) or African American (5%). Individuals carrying known mutations in the Mendelian genes for AD (APP, PSEN1, PSEN2) or Frontotemporal Dementia (GRN, MAPT, C9ORF72) were excluded.  AD definition is based on a combination of both clinical and pathological information if available. Pathologic diagnosis will overrule clinical diagnosis.  Autopsy information is provided if available, but is not a requirement for enrollment.


Dataset Name Type Cases/Controls Total Subjects
NG00030 WashU1 GWAS GWAS
208 / 350 678
NG00035 GWAS of CSF tau levels identifies risk variants for AD


NA 1934
NG00049 CSF Summary Statistics- Cruchaga et al. (2013) Summary Statistics    
NG00050 GWAS of CLU, A potential endophenotype for Alzheimer's disease GWAS
NA 673
NG00051 SORL1 coding variants and risk for AD Targeted Genotyping
Targeted Sequencing
sEOAD- 212/167
sLOAD- 134/266
fLOAD- 866/324
sEOAD- 379
sLOAD- 400
fLOAD- 1190
NG00052 CLU, A potential endophenotype for AD: Summary Statistics- Deming et al. (2016) Summary Statistics NA NA
NG00055 CSF Aβ/ptau Summary Statistics - Deming Y et al. (2017) Summary Statistics NA NA
NG00067 Knight ADRC - WES Whole Exome Sequencing 253/346 650
NG00083 Circular RNAs in Alzheimer Disease Brains - RNA-seq Data Summary Statistics/RNA-Seq NA NA
NG00085 ExomeChip - WashU GWAS 519 / 349 868
NG00087 WashU2 GWAS GWAS
38 / 94


NG00089 CSF TREM2 Summary Statistics Summary Statistics NA NA
NG00102 Genomic and multi-tissue proteomic integration for understanding the genetic architecture of neurological diseases Individual-level data (proteomics + array-based genotype data after imputation) and summary statistics CSF- 201/612
Plasma- 167/357
Brain- 234/22
CSF- 817
Plasma- 528
Brain- 343
NG00108 Profiling microglia expression profiles in AD using single-nuclei RNA-seq Single Cell RNA Sequencing 44 44
NG00113 Metabolomic and lipidomic signatures in Alzheimer disease brains Metabolomics 397/26 436
NG00114 DNA Methylation in Alzheimer disease brains Methylation 383/35 431
NG00127 Knight ADRC GWAS GWAS 2186 / 1783 4496
NG00128 COVID-19 Proteomics Proteomics 332 / 150 482
NG00130 Large scale CSF proteogenomic atlas Summary Statistics NA NA
NG00131 Large scale genetics study on CSF and brain metabolite levels Summary Statistics NA NA


This work was supported by grants from the National Institutes of Health (R01AG044546, P01AG003991, RF1AG053303, R01AG058501, U01AG058922, RF1AG058501 and R01AG057777). The recruitment and clinical characterization of research participants at Washington University were supported by NIH P50 AG05681, P01 AG03991, and P01 AG026276. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry at Washington University School of Medicine. We thank the contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry at Washington University School of Medicine.